Promising development for the genOway Shanghai joint venture

The biotechnology company genOway, listed on Euronext Growth, reports significant progress in the development of its joint venture in China. Created in October 2023, genOway Shanghai is asserting itself in the Chinese preclinical research market, the third largest in the world.

The joint venture quickly set up an operational production unit. In addition, it has obtained the necessary authorizations to import and produce immuno-oncology models. Currently, seven models are available in China, with a goal of 25 models soon.

The commercial structuring has also seen notable success with the hiring of three experienced salespeople and four immunologist technical salespeople. genOway Shanghai has already made its first sales and obtained referrals from large Chinese CROs.